Telesis Bio, Inc. (TBIO)

Revenue by Product

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Collaboration	8.69M
Collaboration Growth	30.68%
BioXP Systems	6.55M
BioXP Systems Growth	-1.57%
Services	6.23M
Services Growth	-23.08%
BioXP Kits	3.20M
BioXP Kits Growth	8.48%
Royalties and Other	2.84M
Royalties and Other Growth	3.13%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
North America	12.31M
North America Growth	56.62%
Europe/ Middle East/ Africa	2.24M
Europe/ Middle East/ Africa Growth	46.45%
Asia Pacific	1.44M
Asia Pacific Growth	-5.85%